Valve Disease

33 Matching Facts

Search matching Facts:
No results to display
    • Cost-effectiveness of TAVR in sSAS patients
      Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
    • Cost-effectiveness of SAVR
      The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
    • Life expectancy and quality of life gains from AVR
      A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years…  
    • Disease specific status and generic health status improvements from TAVR and SAVR
      Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…  
    • Satisfaction with HVD Treatment
      Among treated heart valve disease (HVD), 96% express “full satisfaction” and 78% are “very satisfied” with their treatment.  
    • Improvements in QoL from TAVR in SAS patients
      Symptomatic aortic stenosis (SAS) patients who underwent transcatheter aortic valve replacement (TAVR) experienced quality of life (QoL) improvements from 5.3 at baseline (10 point scale with 10=best imaginable health state)…  
    • TAVR Success in sSAS Patients
      A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
    • TAVR Procedures 2011 – 2015
      From approval in 2011 through 2015, >54,000 transcatheter aortic valve replacements (TAVRs) were performed in 418 centers in 48 states.  
    • TAVR v. SAVR in Intermediate-Risk SAS Patients
      At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
    • Survival Rates of SAS Patients with and without SAVR
      Patients with severe aortic stenosis (SAS) ages 80+ who underwent surgical aortic valve replacement (SAVR) have 1-year, 2-year, and 5-year survival rates of 87%, 78%, and 68% respectively — compared with…  
    • Surgical Aortic Valve Replacements in 2010
      In 2010, ~67,500 surgical aortic valve replacements (SAVR) were performed in the U.S.  
    • 2016 prevalence of Americans 65+ who had AVD
      In 2016, an estimated 5.2 million U.S. adults ages 65+ had aortic valve disease (AVD).   Note: Alliance for Aging Research generated statistic, based on 2005 percentage prevalence estimates by Bach et al. 2007  
    • 2016 prevalence of aortic valve disease in America
      In 2016, as many as 5.8 million U.S. adults had aortic valve disease (AVD). Note: Alliance for Aging Research generated statistic, based on 2005 percentage prevalence estimates by Bach et al. 2007  
    • Undertreatment of patients with sSAS
      AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on.  
    • Detection rate of heart murmurs
      More than 40% of heart murmurs — detected with a stethoscope and sometimes the first sign of heart valve disease (HVD) — are missed by family practitioners.  
    • Many cases of HVD are diagnosed during a routine physical check-up
      Six in 10 patients did not have or recognize symptoms of heart valve disease (HVD) and were only diagnosed after going to their doctor for a regular check-up or a…  
    • HVD patients knew little prior to their diagnosis
      More than 2/3 of valve disease patients knew a limited amount or nothing about heart valve disease (HVD) before their diagnosis.  
    • Many Americans know nothing about HVD
      Of those Americans surveyed ages 65+, 30% know nothing about heart valve disease (HVD).  
    • American knowledge of HVD
      A survey of Americans found that only 1 in 4 know “somewhat” or a “great deal” about heart valve disease (HVD). Forty percent know nothing about the disease.  
    • Projections of Significant Heart Valve Disease — Diagnosed & Undiagnosed — in the 65+ U.K. Population
       
    • Five-year health care resource use in medically managed SAS patients
       
    • Mean 5-Year Cumulative Total Medical Costs Per Medically Managed (No AVR) Severe AS Patient
       
    • SAS patient hospitalization costs
      Symptomatic aortic stenosis (SAS) patients who do not undergo treatment cost Medicare as much as $1.3 billion each year due to rehospitalization, prolonged stays, admissions to skilled nursing facilities, and…  
    • Aortic valve disease costs
      Aortic valve disease (AVD) (symptomatic and asymptomatic) costs the U.S. $10.2 billion in direct costs each year.  
    • Survival Rates Over 5 Years for Patients with Medically Managed Severe Aortic Stenosis
       
    • Increased hospital admissions and prolonged length of stay for patients who do not undergo treatment
      Medicare severe symptomatic aortic stenosis (sSAS) patients who do not undergo treatment have an average of 1.9 hospital admissions per year and prolonged lengths of stay — 11.5 hospital days…  
    • All-cause mortality for aortic valve disorders
      In 2014, all-cause mortality for aortic valve disorders was 34,408 in the U.S.  
    • 1 and 6-month mortality rates without treatment for sSAS
      Waiting for treatment for severe symptomatic aortic stenosis (sSAS) can be deadly, with 1-month mortality at 3.7% and 6-month mortality at 11.6% (measured from the time intervention was recommended).  
    • Lifespan of Medicare patients with sSAS who do not undergo treatment
      Medicare patients with severe symptomatic aortic stenosis (sSAS) who do not undergo treatment have an average lifespan of 1.8 years.  
    • Survival rates of sSAS patients who do not undergo valve replacement
      Patients with severe symptomatic aortic stenosis (sSAS) who do not undergo valve replacement have survival rates as low as 50% at two years and 20% at 5 years after the…  
    • Prevalence of AS in Americans 75+
      An estimated 12.4%, or ~2.5 million people ages 75+ in North America, have AS.  
    • Low detection rates for AS
      Prevalence estimates for AS are likely low. A U.K. population screening found previously undetected HVD in 1 in 2 adults ages 65+.  
    • Aortic stenosis impacts majority of heart valve disease patients
      Aortic stenosis (AS) is among the most common forms of heart valve disease (HVD), affecting 2% to 3% of the adult U.S. population.